topbanner


Development of microfluidic high-throughput bioassays based on 3D matrix-supported spheroids

The aim of this project is to design novel microfluidic devices with associated procedures that allow the generation and long-term culture of 3D tumour spheroids in order to perform miniaturised high-throughput drug screening assays. Physiologically relevant 3D cancer models are studied using both cell lines and primary human tissue from biopsies for a long period of time within the microfluidics. Microfluidic passive networks are used to maximise the analysis possible from limited cell sources.

wellP1.


Theresa Christ

Co-Investigators:

Dr M. Zagnoni, Univ. Strathclyde

Prof D. Flint, Univ. Strathclyde

Dr M. Boyd, Univ. Strathclyde

Dr J. Edwards, Univ. Glasgow

AMS Biotechnology (Europe) Ltd


LOC platform for high-throughput screening of anti-cancer therapeutics and delivery agents in prostate cancer

The aim of this studentship is to develop a new platform technology to screen emerging anti-cancer therapeutics and delivery agents (i.e., cell-penetrating peptides) being developed in the Beatson Institute and the University of Strathclyde for the treatment of castrate-resistant prostate cancer (CRPC). This studentship will involve developing a microfluidics platform that will enable screening the parameters of drug concentration, cell type, cell penetration in 3D structures and assaying the effects of the drug in a high-throughput format.

wellP2.


Scott Gilmartin

Co-Investigators:

Dr M. Zagnoni, Univ. Strathclyde

Dr G. Burley, Univ. Strathclyde

Prof H. Leung, Beatson Institute


Feasibility study to use enhanced fluorescent imaging and microfluidic technology for high-throughput drug screening of patient derived tumour cell models

The aim of this project is to apply novel microfluidic systems for the 3D culture of primary tumour cell models (http://www.amsbio.com/cancer-model-media-cell-line.aspx). By combining continuous bright-field phase contrast measurements of tumour spheroid response to drugs in microfluidics with fluorescent reporters of pH and metabolic activity, we will provide new sensing techniques to create high-throughput and low cost screening assays using 3D microtumours from patient-derived material, overcoming the current limitations for oncology drug discovery and development of personalised treatment.

wellP3.


Dr Graham Robertson

Co-Investigators:

Dr M. Zagnoni, Univ. Strathclyde

AMS Biotechnology (Europe) Ltd


SPONSORS


"Copyright © 2018 by Michele Zagnoni”